Schizophrenia Research
Volume 100, Issue 1 , Pages 97-107 , March 2008

Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment

Received 30 July 2007 ,Revised 17 October 2007 ,Accepted 25 October 2007.

References 

  1. Angermeyer MC, Kilian R, Matschinger H. WHOQOL-100 AND WHAOQOL-BREF. Göttingen: Hogrefe; 2000;
  2. Barnes TRE. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989;154:672–676
  3. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J. Clin. Psychiatry. 2002;63(suppl. 4):12–19
  4. Casey DE, Povisen UJ, Meidahl B, Gerlach J. Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment. Psychopharmacol. Bull. 1986;22:250–253
  5. Clark WG, Del Guidice J. Principles of Psychopharmacology. New York: Academic Press; 1970;
  6. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry. 2004;161:414–425
  7. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry. 2003;60:553–564
  8. Dietmaier O, Laux G. Übersichtstabellen. In:  Riederer P,  Laux G,  Pöldinger W editor. Neuro-Psychopharmaka, Bd.4. Wien: Springer; 1992;p. 197–213
  9. Dietmaier O, Laux G. Übersichtstabellen. In:  Riederer P,  Laux G,  Pöldinger W editor. Neuro-Psychopharmaka. Ein Therapie-Handbuch, Bd.4, 2.Auflage. Wien: Springer; 1998;p. 505–525
  10. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol. Psychiatry. 2003;53:1142–1145
  11. Dose M. Neuroleptic-induced vs. genuine motor disorders. In:  Jahn T editors. Movement disorders in mental disorders. Berlin: Springer; 2004;p. 29–59
  12. Eberhard J, Lindström E, Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Internat. Clin. Psychopharmacol. 2006;21:35–42
  13. Fahn S, Elton RL members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In:  Fahn S,  Marsden CD,  Goldstein M editor. Recent Developments in Parkinson's Disease. vol. 2:Florham Park NJ: Macmillan Health Care Information; 1987;p. 153–164
  14. Farde L, Mordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 1992;49:538–544
  15. Gardner DM, Baldessarini J, Waraich P. Modern antipsychotic drugs: a critical overview. Can. Med. Assoc. J. 2005;172:1703–1711
  16. Geddes J, Freemantle N, Harrison P, Bebbington P for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371–1376
  17. Guy W. In: ECDEU Assessment Manual for Psychopharmacology, revised. Washington DC: United States Department of Health, Education and Welfare; 1976;p. 534–537
  18. Halliday J, Farrington S, McDonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale schizophrenia surveys 23: movement disorders. Br. J. Psychiatry. 2002;181:422–427
  19. Hautzinger M, Bailer M, Worall H, Keller F. Beck Depressions-Inventar (BDI), Bearbeitung der deutschen Ausgabe. Bern: Huber; 1995;
  20. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disoders in chronic schizophrenia inpatients. Am. J. Psychiatry. 2004;161:160–163
  21. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr. Bull. 1993;19:303–315
  22. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch. Gen. Psychiatry. 2006;63:1079–1087
  23. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 rexceptor explation the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry. 2001;158:360–369
  24. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 2000;157:514–520
  25. Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr. Res. 2005;81:139–143
  26. Kilian R, Dietrich S, Toumi M, Angermeyer MC. Quality of life in persons with schizophrenia in outpatient treatment with first- of second-generation antipsychotics. Acta Psychiatr. Scand. 2004;110:108–118
  27. Lane RD, Glazer WM, Hansen TE, Bermann WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal involuntary movement scale. J. Nerv. Ment. Dis. 1985;173:353–357
  28. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581–1589
  29. Levin H, Chengappa KN, Kambhampati RK, Mahdavi N, Ganguli R. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schzophrenic patients?. J. Clin. Psychiatry. 1992;53:248–251
  30. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl. J. Med. 2005;353:1209–1223
  31. Llorca P-M, Chereau I, Bayle F-J, Lancon C. Tardive dyskinesias and antipsychotics: a review. Eur. Psychiatry. 2002;17:129–138
  32. Marshall DL, Hazlet TK, Gardner JS, Blough DK. Neuroleptic drug exposure and incidence of tardive dyskinesia: a records-based case-control study. J. Manag. Care Pharm. 2002;8:259–265
  33. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarriés J, Bermejo F. Unified Parkinson's disease rating scale characteristics and structure. Mov. Disord. 1994;9:76–83
  34. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989;251:238–246
  35. Modestin J, Stephan PL, Erni T, Umari T. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr. Res. 2000;42:223–230
  36. Mortimer AM, Al-Abib AOA. Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study. Int. J. Soc. Psychiatry. 2007;53:99–107
  37. In:  Morant J editors. Arzneimittel Kompendium der SchweizR, 25.Auflage. Basel: Documed; 2004;
  38. Nair CJ, Josiassen RC, Abraham G, Stanilla JK, Tracy JI, Simpson GM. Does akathisia influence psychopathology in psychotic patients treated with clozapine?. Biol. Psychiatry. 1999;45:1376–1383
  39. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191–208
  40. Ritsner M, Bibel A, Perelroyzen B, Kurs R, Jabarin M, Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice. J. Clin. Psychopharmacol. 2004;24:582–591
  41. Schatzberg AF, Cole JO, DeBattista C. In: Manual of Clinical Psychopharmacology, 4.Edition. Washington DC: American Psychiatric Publishing; 2002;p. 159–243
  42. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry. 1982;39:486–487
  43. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv. Rev. Psychiatry. 2006;14:152–164
  44. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J. Clin. Psychiatry. 1997;58:318–322
  45. Toffelson GTD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry. 1997;154:1248–1254
  46. Van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesa, parkinsonism and akathisia. The Curaçao extrapyramidal syndromes study I. Schizophr. Res. 1996;19:195–203
  47. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry. 2003;64:663–667

PII: S0920-9964(07)00495-1

doi: 10.1016/j.schres.2007.10.018

Schizophrenia Research
Volume 100, Issue 1 , Pages 97-107 , March 2008

Article Tools